Lithium co-crystals and an additional neuropsychiatric agent for treatment of neuropsychiatric disorders

Patent metadata

Field	Value
Publication number	US-9603869-B2
Application number	US-201615161202-A
Country	US
Kind code	B2
Filing date	May 21, 2016
Priority date	May 22, 2015
Publication date	Mar 28, 2017
Grant date	Mar 28, 2017

Abstract

The invention concerns methods and compositions for treating a neuropsychiatric disorder, wherein the method comprises administering an effective amount of a co-crystal of lithium to a subject in need thereof, wherein the co-crystal comprises lithium, or a pharmaceutically acceptable salt thereof, and an amino acid.

First claim

We claim:

1. A method for treating a neuropsychiatric disorder, comprising administering an effective amount of a co-crystal of lithium to a subject having the neuropsychiatric disorder, wherein the co-crystal comprises lithium, or a pharmaceutically acceptable salt thereof, and an amino acid; and administering an additional agent for treating the neuropsychiatric disorder before, during, or after the administration of the lithium co-crystal.

2. The method of claim 1 , wherein the co-crystal comprises a pharmaceutically acceptable salt of lithium, and an amino acid.

3. The method of claim 1 , wherein the pharmaceutically acceptable salt is lithium salicylate or lithium hydroxide.

4. The method of claim 1 , wherein the amino acid is L-proline.

5. The method of claim 1 , wherein the co-crystal comprises lithium salicylate and L-proline.

6. The method of claim 1 , wherein the neuropsychiatric disorder is a neurodegenerative disorder.

7. The method of claim 6 , wherein the neurodegenerative disorder is Alzheimer's disease, Parkinson's disease, or amyotrophic laterals sclerosis (ALS).

8. The method of claim 1 , wherein the neuropsychiatric disorder is a mood disorder, schizoaffective disorder, tic disorder, or suicidality.

9. The method of claim 1 , wherein the neuropsychiatric disorder is Alzheimer's disease or other dementia, and the additional agent is a cholinesterase inhibitor, N-methyl D-aspartate antagonist, vitamin E, or a combination of two or more of the foregoing.

10. The method of claim 9 , wherein the additional agent is donepezil, rivastigmine, galantamine, memantine, or a combination of two or more of the foregoing.

11. The method of claim 1 , wherein the additional agent is an anti-depressant, anti-convulsant, or mood stabilizer.

12. The method of claim 1 , wherein the additional agent is a selective serotonin reuptake inhibitor (SSRI), serotonin-noroepinephrine reuptake inhibitor (SNRI), serotonin antagonist and reuptake inhibitor (SARI), monamine oxidase inhibitor (MAOI), carboxamide, fructose derivative, triazine, or a combination of two or more of the foregoing.

13. The method of claim 1 , wherein the lithium co-crystal is administered to the subject in a composition comprising the lithium co-crystal and a pharmaceutically acceptable carrier.

Assignees

• Tan Jun
• Smith Adam John
• Shytle Roland Douglas
• Univ South Florida

Inventors

• Tan Jun
• Smith Adam John
• Shytle Roland Douglas

Classifications

• A61K33/00 Primary

  Medicinal preparations containing inorganic active ingredients · CPC title

• A61K38/00

  Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) · CPC title

• A61K47/48061

  Human Necessities · mapped topic

• A61K47/48038

  Human Necessities · mapped topic

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title